<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.jneuroinflammation.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Journal of Neuroinflammation - Latest Articles</title>
        <link>http://www.jneuroinflammation.com</link>
        <description>The latest research articles published by Journal of Neuroinflammation</description>
        <dc:date>2010-08-26T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/49" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/48" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/47" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/46" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/45" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/44" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/43" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/42" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/41" />
                                <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/7/1/40" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/49">
        <title>Tumor necrosis factor alpha sensitizes spinal cord TRPV1 receptors to the endogenous agonist N-oleoyldopamine </title>
        <description>Modulation of synaptic transmission in the spinal cord dorsal horn is thought to be involved in the development and maintenance of different pathological pain states. The proinflamatory cytokine, tumor necrosis factor alpha (TNFalpha), is an established pain modulator in both the peripheral and the central nervous system. Up-regulation of TNFalpha and its receptors (TNFR) in dorsal root ganglion (DRG) cells and in the spinal cord has been shown to play an important role in neuropathic and inflammatory pain conditions. Transient receptor potential vanilloid 1 (TRPV1) receptors are known as molecular integrators of nociceptive stimuli in the periphery, but their role on the spinal endings of nociceptive DRG neurons is unclear. The endogenous TRPV1 receptor agonist N-oleoyldopamine (OLDA) was shown previously to activate spinal TRPV1 receptors. In our experiments the possible influence of TNFalpha on presynaptic spinal cord TRPV1 receptor function was investigated. Using the patch-clamp technique, miniature excitatory postsynaptic currents (mEPSCs) were recorded in superficial dorsal horn neurons in acute slices after incubation with 60 nM TNFalpha. A population of dorsal horn neurons with capsaicin sensitive primary afferent input recorded after the TNFalpha pretreatment had a basal mEPSC frequency of 1.35 +/- 0.20 Hz (n = 13), which was significantly higher when compared to a similar population of neurons in control slices (0.76 +/- 0.08 Hz; n = 53; P &lt; 0.01). In control slices application of a low concentration of OLDA (0.2 uM) did not evoke any change in mEPSC frequency. After incubation with TNFalpha, OLDA (0.2 uM) application to slices induced a significant increase in mEPSC frequency (155.5 +/- 17.5%; P &lt; 0.001; n = 10). Our results indicate that TNFalpha may have a significant impact on nociceptive signaling at the spinal cord level that could be mediated by increased responsiveness of presynaptic TRPV1 receptors to endogenous agonists. This could be of major importance, especially during pathological conditions, when increased levels of TNFalpha and TNFR are present in the spinal cord.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/49</link>
                <dc:creator>Diana Spicarova</dc:creator>
                <dc:creator>Jiri Palecek</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:49</dc:source>
        <dc:date>2010-08-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-49</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>49</prism:startingPage>
        <prism:publicationDate>2010-08-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/48">
        <title>Neurotensin is increased in serum of young children with autistic disorder</title>
        <description>Autism spectrum disorders (ASD) are a group of pervasive neurodevelopmental disorders diagnosed in early childhood. They are associated with a set of &quot;core symptoms&quot; that include disabilities in social interaction skills, verbal and non-verbal communication, as well as repetitive and stereotypic behaviors. There is  no definite pathogenetic mechanism or diagnostic tests. Many children with ASD also have &quot;allergic-like&quot; symptoms, but test negative implying mast cell activation by non-allergic triggers. We measured by Milliplex arrays serum levels of 3 neuropeptides that could stimulate mast cells in children with autistic disorder (n=19; 16 males and 3 females; mean age 3.0 +/- 0.4 years) and healthy,  unrelated controls (n=16; 13 males and 3 females; mean age 3 +/- 1.2 years). Only neurotensin (NT) was significantly increased from 60.5 +/- 6.0 pg/ml in controls to 105.6 +/- 12.4 pg/ml in autistic disorder (p=0.004). There was no statistically significant difference in the serum levels of beta-endorphin or substance P (SP). NT could stimulate immune cells, especially mast cells, and/or have direct effects on brain inflammation and ASD.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/48</link>
                <dc:creator>Asimenia Angelidou</dc:creator>
                <dc:creator>Konstantinos Francis</dc:creator>
                <dc:creator>Magdalini Vasiadi</dc:creator>
                <dc:creator>Konstantinos-Dionysios Alysandratos</dc:creator>
                <dc:creator>Bodi Zhang</dc:creator>
                <dc:creator>Athanasios Theoharides</dc:creator>
                <dc:creator>Lefteris Lykouras</dc:creator>
                <dc:creator>Kyriaki Sideri</dc:creator>
                <dc:creator>Dimitrios Kalogeromitros</dc:creator>
                <dc:creator>Theoharis Theoharides</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:48</dc:source>
        <dc:date>2010-08-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-48</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>48</prism:startingPage>
        <prism:publicationDate>2010-08-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/47">
        <title>Hypothalamic abnormalities and Parkinsonism associated with H1N1 influenza infection</title>
        <description>ObjectiveTo describe a case of a young adult with severe H1N1 influenza illness associated with hypothalamic abnormalities and post-influenza parkinsonism.DesignCase report.PatientA 22-year-old woman with H1N1 influenza infection developed encephalopathy followed by diverse hypothalamic dysfunction manifestations, sleeplessness, and persistent parkinsonian features.
Results:
CSF analysis, brain imaging and EEG ruled out hypoxic brain injury or other illnesses.
Conclusions:
A number of viruses have been associated with both acute and chronic parkinsonism. A link between parkinsonism and influenza viruses is somewhat controversial. This is the first reported case of parkinsonism following an H1N1 influenza infection.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/47</link>
                <dc:creator>Alejandra Gonzalez Duarte</dc:creator>
                <dc:creator>Lucia Magana Zamora</dc:creator>
                <dc:creator>Carlos Cantu Brito</dc:creator>
                <dc:creator>Guillermo Garcia Ramos</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:47</dc:source>
        <dc:date>2010-08-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-47</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>47</prism:startingPage>
        <prism:publicationDate>2010-08-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/46">
        <title>Resveratrol differentially modulates inflammatory responses of microglia and astrocytes</title>
        <description>Background:
Inflammatory responses in the CNS mediated by activated glial cells play an important role in host-defense but are also involved in the development of neurodegenerative diseases. Resveratrol is a natural polyphenolic compound that has cardioprotective, anticancer and anti-inflammatory properties. We investigated the capacity of resveratrol to protect microglia and astrocyte from inflammatory insults and explored mechanisms underlying   different inhibitory effects of resveratrol on microglia and astrocytes.
Methods:
A murine microglia cell line (N9), primary microglia, or astrocytes were stimulated by LPS with or without different concentrations of resveratrol. The expression and release of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6, MCP-1) and iNOS/NO by the cells were measured by PCR/real-time PCR and ELISA, respectively. The phosphorylation of the MAP kinase superfamily was analyzed by western blotting, and activation of NF-kappaB and AP-1 was measured by luciferase reporter assay and/or electrophoretic mobility shift assay.
Results:
We found that LPS stimulated the expression of TNF-alpha, IL-1beta, IL-6, MCP-1 and iNOS in murine microglia and astrocytes in which MAP kinases, NF-kappaB and AP-1 were differentially involved. Resveratrol inhibited LPS-induced expression and release of TNF-alpha, IL-6, MCP-1, and iNOS/ NO in both cell types with more potency in microglia, and inhibited LPS-induced expression of IL-1beta in microglia but not astrocytes. Resveratrol had no effect on LPS-stimulated phosphorylation of ERK1/2 and p38 in microglia and astrocytes, but slightly inhibited LPS-stimulated phosphorylation of JNK in astrocytes. Resveratrol inhibited LPS-induced NF-kappaB activation in both cell types, but inhibited AP-1 activation only in microglia.
Conclusion:
These results suggest that murine microglia and astrocytes produce proinflammatory cytokines and NO in response to LPS in a similar pattern with some differences in signaling molecules involved, and further suggest that resveratrol exerts anti-inflammatory effects in microglia and astrocytes by inhibiting different proinflammatory cytokines and key signaling molecules.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/46</link>
                <dc:creator>Xiaofeng Lu</dc:creator>
                <dc:creator>Lili Ma</dc:creator>
                <dc:creator>Lingfei Ruan</dc:creator>
                <dc:creator>Yan Kong</dc:creator>
                <dc:creator>Haiwei Mou</dc:creator>
                <dc:creator>Zhijie Zhang</dc:creator>
                <dc:creator>Zhijun Wang</dc:creator>
                <dc:creator>Ji Ming Wang</dc:creator>
                <dc:creator>Yingying Le</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:46</dc:source>
        <dc:date>2010-08-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-46</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>46</prism:startingPage>
        <prism:publicationDate>2010-08-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/45">
        <title>Effects of mitochondrial dysfunction on the immunological properties of microglia</title>
        <description>Background:
Neurodegenerative diseases are characterized by both mitochondrial dysfunction and activation of microglia, the macrophages of the brain. Here, we investigate the effects of mitochondrial dysfunction on the activation profile of microglial cells.
Methods:
We incubated primary mouse microglia with the mitochondrial toxins 3-nitropropionic acid (3-NP) or rotenone. These mitochondrial toxins are known to induce neurodegeneration in humans and in experimental animals. We characterized lipopolysaccharide- (LPS-) induced microglial activation and the alternative, interleukin-4- (IL-4-) induced microglial activation in these mitochondrial toxin-treated microglial cells.
Results:
We found that, while mitochondrial toxins did not affect LPS-induced activation, as measured by release of tumor necrosis factor &#945; (TNF-&#945;), interleukin-6 (IL-6) and interleukin-1&#946; (IL-1&#946;), they did inhibit part of the IL-4-induced alternative activation, as measured by arginase activity and expression, induction of insulin-like growth factor 1 (IGF-1) and the counteraction of the LPS induced cytokine release.
Conclusions:
Mitochondrial dysfunction in microglial cells inhibits part of the IL-4-induced alternative response. Because this alternative activation is considered to be associated with wound healing and an attenuation of inflammation, mitochondrial dysfunction in microglial cells might contribute to the detrimental effects of neuroinflammation seen in neurodegenerative diseases.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/45</link>
                <dc:creator>Annette Ferger</dc:creator>
                <dc:creator>Loretta Campanelli</dc:creator>
                <dc:creator>Valentina Reimer</dc:creator>
                <dc:creator>Katharina Muth</dc:creator>
                <dc:creator>Irma Merdian</dc:creator>
                <dc:creator>Albert Ludolph</dc:creator>
                <dc:creator>Anke Witting</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:45</dc:source>
        <dc:date>2010-08-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-45</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>45</prism:startingPage>
        <prism:publicationDate>2010-08-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/44">
        <title>Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct</title>
        <description>Regulatory T cells, Tregs, are a subset of lymphocytes that have immunosuppressive attributes. They are elevated in blood of glioblastoma patients and within this tumor&apos;s tissue itself. Indoleamine 2,3-dioxygenase, IDO, converts tryptophan to kynurenine. IDO activity enhances Treg formation by pathways that are unknown. Experimentally, inhibition of IDO decreases Treg function and number in rodents. The common anti-viral agent acyclovir inhibits IDO. Acyclovir may thereby decrease Treg function in glioblastoma. If it can be confirmed that Treg counts are elevated in glioblastoma patients&apos; tumor tissue, and if we can document acyclovir&apos;s lowering of tissue Treg counts by a small trial of acyclovir in pre-operative glioblastoma patients, a trial of acyclovir effect on survival should be done given the current poor prognosis of glioblastoma and the well-established safety and low side effect burden of acyclovir.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/44</link>
                <dc:creator>Johan Soderlund</dc:creator>
                <dc:creator>Sophie Erhardt</dc:creator>
                <dc:creator>Richard Kast</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:44</dc:source>
        <dc:date>2010-08-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-44</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>44</prism:startingPage>
        <prism:publicationDate>2010-08-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/43">
        <title>Central Administration of Lipopolysaccharide Induces Depressive-like Behavior in Vivo and Activates Brain Indoleamine 2,3 Dioxygenase In Murine Organotypic Hippocampal Slice Cultures </title>
        <description>Background:
Transient stimulation of the innate immune system by an intraperitoneal injection of lipopolysaccharide (LPS) activates peripheral and central expression of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) which mediates depressive-like behavior. It is unknown whether direct activation of the brain with LPS is sufficient to activate IDO and induce depressive-like behavior.
Methods:
Sickness and depressive-like behavior in C57BL/6J mice were assessed by social exploration and the forced swim test, respectively. Expression of cytokines and IDO mRNA was measured by real-time RT-PCR and cytokine protein was measured by enzyme-linked immunosorbent assays (ELISAs). Enzymatic activity of IDO was estimated as the amount of kynurenine produced from tryptophan as determined by high pressure liquid chromatography (HPLC) with electrochemical detection.
Results:
Intracerebroventricular (i.c.v.) administration of LPS (100 ng) increased steady-state transcripts of TNF&#945;, IL-6 and the inducible isoform of nitric oxide synthase (iNOS) in the hippocampus in the absence of any change in IFN&#947; mRNA. LPS also increased IDO expression and induced depressive-like behavior, as measured by increased duration of immobility in the forced swim test. The regulation of IDO expression was investigated using in situ organotypic hippocampal slice cultures (OHSCs) derived from brains of newborn C57BL/6J mice. In accordance with the in vivo data, addition of LPS (10 ng/ml) to the medium of OHSCs induced steady-state expression of mRNA transcripts for IDO that peaked at 6 h and translated into increased IDO enzymatic activity within 8 h post-LPS. This activation of IDO by direct application of LPS was preceded by synthesis and secretion of TNF&#945; and IL-6 protein and activation of iNOS while IFN&#947; expression was undetectable.
Conclusion:
These data establish that activation of the innate immune system in the brain is sufficient to activate IDO and induce depressive-like behavior in the absence of detectable IFN&#947;. Targeting IDO itself may provide a novel therapy for inflammation-associated depression.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/43</link>
                <dc:creator>Xin Fu</dc:creator>
                <dc:creator>Samantha Zunich</dc:creator>
                <dc:creator>Jason O'Connor</dc:creator>
                <dc:creator>Annemieke Kavelaars</dc:creator>
                <dc:creator>Robert Dantzer</dc:creator>
                <dc:creator>Keith Kelley</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:43</dc:source>
        <dc:date>2010-08-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-43</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>43</prism:startingPage>
        <prism:publicationDate>2010-08-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/42">
        <title>Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice</title>
        <description>Background:
The enzyme cytosolic phospholipase A2 alpha (cPLA2&#945;) has been implicated in the progression of cerebral injury following ischemia and reperfusion. Previous studies in rodents suggest that cPLA2&#945; enhances delayed injury extension and disruption of the blood brain barrier many hours after reperfusion. In this study we investigated the role of cPLA2&#945; in early ischemic cerebral injury.
Methods:
Middle cerebral artery occlusion (MCAO) was performed on cPLA2&#945;+/+ and cPLA2&#945;-/- mice for 2 hours followed by 0, 2, or 6 hours of reperfusion. The levels of cPLA2&#945;, cyclooxygenase-2, neuronal morphology and reactive oxygen species in the ischemic and contralateral hemispheres were evaluated by light and fluorescent microscopy. PGE2 content was compared between genotypes and hemispheres after MCAO and MCAO and 6 hours reperfusion. Regional cerebral blood flow was measured during MCAO and phosphorylation of relevant MAPKs in brain protein homogenates was measured by Western analysis after 6 hours of reperfusion.
Results:
Neuronal cPLA2&#945; protein increased by 2-fold immediately after MCAO and returned to pre-MCAO levels after 2 hours reperfusion. Neuronal cyclooxygenase-2 induction and PGE2 concentration were greater in cPLA2&#945;+/+ compared to cPLA2&#945;-/- ischemic cortex. Neuronal swelling in ischemic regions was significantly greater in the cPLA2&#945;+/+ than in cPLA2&#945;-/- brains (+/+: 2.2 &#177; 0.3 fold vs. -/-: 1.7 &#177; 0.4 fold increase; P &lt; 0.01). The increase in reactive oxygen species following 2 hours of ischemia was also significantly greater in the cPLA2&#945;+/+ ischemic core than in cPLA2&#945;-/- (+/+: 7.12 &#177; 1.2 fold vs. -/-: 3.1 &#177; 1.4 fold; P &lt; 0.01). After 6 hours of reperfusion ischemic cortex of cPLA2&#945;+/+, but not cPLA2&#945;-/-, had disruption of neuron morphology and decreased PGE2 content. Phosphorylation of the MAPKs-p38, ERK 1/2, and MEK 1/2-was significantly greater in cPLA2a+/+ than in cPLA2&#945;-/- ischemic cortex 6 hours after reperfusion.
Conclusions:
These results indicate that cPLA2&#945; modulates the earliest molecular and injury responses after cerebral ischemia and have implications for the potential clinical use of cPLA2&#945; inhibitors.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/42</link>
                <dc:creator>Koji Kishimoto</dc:creator>
                <dc:creator>Rung-Chi Li</dc:creator>
                <dc:creator>Jian Zhang</dc:creator>
                <dc:creator>Judith Klaus</dc:creator>
                <dc:creator>Kathleen Kibler</dc:creator>
                <dc:creator>Sylvain Dore</dc:creator>
                <dc:creator>Raymond Koehler</dc:creator>
                <dc:creator>Adam Sapirstein</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:42</dc:source>
        <dc:date>2010-07-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-42</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2010-07-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/41">
        <title>Gp91phox (NOX2) in classically activated microglia exacerbates 
traumatic brain injury 
</title>
        <description>Background:
We hypothesized that gp91phox (NOX2), a subunit of NADPH oxidase, generates superoxide anion (O2-) and has a major causative role in traumatic brain injury (TBI). To evaluate the functional role of gp91phox and reactive oxygen species (ROS) on TBI, we carried out controlled cortical impact in gp91phox knockout mice (gp91phox-/-). We also used a microglial cell line to determine the activated cell phenotype that contributes to gp91phox generation.
Methods:
Unilateral TBI was induced in gp91phox-/- and wild-type (Wt) mice (C57/B6J) (25-30 g). The expression and roles of gp91phox after TBI were investigated using immunoblotting and staining techniques. Levels of O2- and peroxynitrite were determined in situ in the mouse brain. The activated phenotype in microglia that expressed gp91phox was determined in a microglial cell line, BV-2, in the presence of IFN&#947; or IL-4.
Results:
Gp91phox expression increased mainly in amoeboid-shaped microglial cells of the ipsilateral hemisphere of Wt mice after TBI. The contusion area, number of TUNEL-positive cells, and amount of O2- and peroxynitrite metabolites produced were less in gp91phox-/- mice than in Wt. In the presence of IFN&#947;, BV-2 cells had increased inducible nitric oxide synthase and nitric oxide levels, consistent with a classical activated phenotype, and drastically increased expression of gp91phox.
Conclusions:
Classical activated microglia promote ROS formation through gp91phox and have an important role in brain damage following TBI. Modulating gp91phox and gp91phox -derived ROS may provide a new therapeutic strategy in combating post-traumatic brain injury.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/41</link>
                <dc:creator>Kenji Dohi</dc:creator>
                <dc:creator>Hirokazu Ohtaki</dc:creator>
                <dc:creator>Tomoya Nakamachi</dc:creator>
                <dc:creator>Sachiko Yofu</dc:creator>
                <dc:creator>Kazue Satoh</dc:creator>
                <dc:creator>Kazuyuki Miyamoto</dc:creator>
                <dc:creator>Dandan Song</dc:creator>
                <dc:creator>Shohko Tsunawaki</dc:creator>
                <dc:creator>Seiji Shioda</dc:creator>
                <dc:creator>Tohru Aruga</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:41</dc:source>
        <dc:date>2010-07-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-41</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>41</prism:startingPage>
        <prism:publicationDate>2010-07-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jneuroinflammation.com/content/7/1/40">
        <title>The acute phase response and soman-induced status epilepticus: temporal, regional and cellular changes in rat brain cytokine concentrations </title>
        <description>Background:
Neuroinflammation occurs following brain injury, including soman (GD) induced status epilepticus (SE), and may contribute to loss of neural tissue and declined behavioral function. However, little is known about this important pathological process following GD exposure. Limited transcriptional information on a small number of brain-expressed inflammatory mediators has been shown following GD-induced SE and even less information on protein upregulation has been elucidated. The purpose of this study is to further characterize the regional and temporal progression of the neuroinflammatory process following acute GD-induced SE.
Methods:
The protein levels of 10 cytokines was quantified using bead multiplex immunoassays in damaged brain regions (i.e., piriform cortex, hippocampus and thalamus) up to 72 hours following seizure onset. Those factors showing significant changes were then localized to neural cells using fluorescent IHC.
Results:
A significant concentration increase was observed in all injured brain regions for four acute phase response (APR) induction cytokines: interleukin (IL)-1&#945;, IL-1&#946;, IL-6, and tumor necrosis factor (TNF)-&#945;. Increases in these APR cytokines corresponded both temporally and regionally to areas of known seizure damage and neuronal death. Neurotoxic cytokines IL-1&#945; and IL-1&#946; were primarily expressed by activated microglia whereas the potentially neuroprotective cytokine IL-6 was expressed by neurons and hypertrophic astrocytes.
Conclusions:
Increases in neurotoxic cytokines likely play an active role in the progression of GD-induced SE neuropathology though the exact role that these and other cytokines play in this process require further study.</description>
        <link>http://www.jneuroinflammation.com/content/7/1/40</link>
                <dc:creator>Erik Johnson</dc:creator>
                <dc:creator>Robert Kan</dc:creator>
                <dc:source>Journal of Neuroinflammation 2010, 7:40</dc:source>
        <dc:date>2010-07-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-2094-7-40</dc:identifier>
        <prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
        <prism:issn>1742-2094</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>40</prism:startingPage>
        <prism:publicationDate>2010-07-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
